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Introduction
Allergic or immune-mediated reactions of the conjunctiva 
are not uncommon. This may, in part, be because the 
conjunctiva has a rich vascular supply, abundant immune 
mediators and direct exposure to the environment.1 Allergic 
conjunctivitis encompasses a wide spectrum, from acute, 
self-limiting forms of seasonal conjunctivitis, to more 
chronic, sight-threatening forms of vernal and atopic 
keratoconjunctivitis. 
The major forms of allergic conjunctivitis involve a type 1 
hypersensitivity reaction, mediated by the degranulation of 
mast cells in response to immunoglobulin E in genetically 
susceptible individuals upon exposure to certain environ-
mental antigens to which they have previously been 
exposed. There is also evidence of type IV hypersensitivity 
in at least some forms.2,3
The purpose of this article was to review the different anti-
allergic ophthalmic drugs in the same sequence in which 
they should be considered in the treatment of a patient 
with an ocular allergy. Thereafter, short descriptions of 
ocular allergic conditions follow to aid accurate diagnosis 
and initiation of appropriate stepwise therapy to reduce the 
potentially adverse effects of allergic conjunctivitis.
An approach to the treatment of allergic 
ocular conditions
A variety of agents is currently available to treat allergic 
conjunctivitis. These are used either alone or in combination 
with each other (Table I):
•	 Elimination	 or	 avoidance	 of	 the	 specific	 allergen:	
Elimination or avoidance of the specific allergen is a 
crucial first step. Although this is not always possible 
or practical, allergy specialists can help with the 
identification and avoidance of the offending allergen 
prior to recommending any allergy remediation measures. 
•	 Lubricants: Chilled, unpreserved lubricants, such 
as polyvinyl alcohol or povidone, e.g. Refresh®, or 
hypromellose or dextran, e.g. Tears Naturale®, help dilute 
and flush antigens from the ocular surface, and thus aid 
in providing symptomatic relief.4
•	 Cold	 compresses: Cold compresses, consisting of ice 
packs wrapped in a clean cloth, may be applied over the 
closed eyes to provide symptomatic relief.2
•	 Topical	 vasoconstrictors:	 Topical vasoconstrictors,	
such as oxymetazoline and nephazoline, cause 
vasoconstriction and decrease vascular permeability. 
They may be used alone, eg. Allergex®, or in combination 
with antihistamines such as antazoline, e.g. Spersallerg®. 
These provide short-term symptomatic relief, but should 
not be used for longer than two weeks because of 
rebound hyperaemia.
•	 Topical	 and	 oral	 antihistamines:	 Topical and oral 
antihistamines act by competitive inhibition of histamine 
at the histamine-1 and histamine-2 receptors, and are 
effective in relieving the acute signs and symptoms 
of allergic eye conditions. Systemic antihistamines 
are indicated for severe symptoms, but may be 
associated with adverse effects, such as drowsiness, 
particularly in the case of the older antihistamines. 
Newer oral antihistamines, such as cetirizine, e.g. 
Zyrtec®, and desloratadine, e.g. Deselex®, have fewer 
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side-effects, and are therefore more preferable. Topical 
antihistamines, such as levocabastine, e.g. Livostin ED®, 
and emedastine, e.g. Emadine®, have a more rapid onset 
and are less likely to cause systemic side-effects, when 
compared to oral preparations. However, their actions 
are generally short-lived, and thus they are preferred in 
milder cases.
•	 Topical	mast	cell	stabilisers:	Topical mast cell stablisers 
inhibit the degranulation of mast cells, thus limiting the 
release of inflammatory mediators, such as histamine. 
Available agents include sodium chromoglycate, e.g. 
Chromohexal®, and lodoxamide, e.g. Alomide®. These 
agents play a largely preventative role and need to be 
used for a few weeks before exerting their maximal 
effect.2 It is important to bring this fact to the attention 
of the user.
•	 Agents	 with	 multiple	 mechanisms	 of	 action	 (MMA):	
Agents with MMA, such as olopatidine, e.g. Patanol®, 
and ketotifen, e.g. Zaditen®, have both antihistamine 
and mast cell-stabilising properties, and are often the 
preferred choice for ophthalmologists and their patients.
•	 Topical	 nonsteroidal	 anti-inflammatory	 drugs	 (NSAIDs):	
Topical NSAIDs,	 such as ketorolac, e.g. Acular®, and 
diclofenac, e.g. Voltaren Ophtha®, inhibit the activity 
of cyclo-oxygenase and may provide added benefit 
in reducing the signs and symptoms associated with 
allergic conjunctivitis.1,2
•	 Topical	 corticosteroids:	 Topical corticosteroids	
inhibit the inflammatory process and are effective in 
reducing the acute symptoms of ocular allergy. Usually, 
they are prescribed in short, intensive courses and 
promptly tapered thereafter.2 Potent preparations, 
such as prednisolone 1%, are generally effective, but 
their protracted use has been associated with well-
known complications, such as glaucoma and cataract 
formation. Newer, less potent corticosteroids, such 
as fluorometholone 0.1%, loteprednol 0.2-0.5% and 
rimexolone 1%, have been designed to lower the risk of 
these side-effects, but are generally not as effective as 
their more potent counterparts. Steroid injections above 
the tarsal plate in the eyelid may also be given in severe 
palpebral disease or to patients who are refractory to 
initial therapy.2
•	 Topical	T-cell	inhibitors:	Topical T-cell inhibitors,	such as 
cyclosporine 1% and tacrolimus 0.03%, e.g. Protopic®, 
may be indicated as steroid-sparing agents, or in 
severe refractory disease under specialist supervision. 
Cyclosporine has been associated with ocular irritation 
and relapses when stopped abruptly.2 Tacrolimus 
ointment has been shown to be very effective in 
modulating conjunctival inflammation in refractory cases 
of ocular allergy.2,5
Table I: Commonly used topical agents in the treatment of allergic 
conjunctivitis
Agent Concentration (%) Frequency of 
administration
Antihistamines
Levocabastine 0.05 q.i.d.
Mast cell stabilisers
Sodium 
chromoglycate
4 q.i.d.
Lodoxamide 0.1 q.i.d.
Antihistamines and mast cell stabilisers
Olopatadine 0.1 b.i.d.
Nonsteroidal anti-inflammatory drugs
Ketolorac 0.5 q.i.d.
Corticosteroids
Dexamethasone 0.1 Variable
Fluorometholone 0.1 Variable
Prednisolone 
acetate
0.12-1 Variable
Immunomodulatory 
Cyclosporine 0.05-2 Variable
Tacrolimus 0.03 b.i.d.
b.i.d: twice a day, q.i.d: four times a day
         10. Topical cyclosporine and tacrolimus
        9. Topical corticosteroids 
       8. Topical nonsteroidal anti-inflammatory drugs
      7. Combined anti-histamine-1 and mast cell stablisers 
     6. Topical mast cell stabilisers 
    5. Topical and oral antihistamine (anti-histamine 1)
   4. Topical vasoconstrictors
  3. Ice (decreases histamine release)
 2. Dilute antigens, e.g. artificial tears
1. Remove antigens
Primary level drugs
Specialist level drugs
Source: Prof D Meyer, Division of Ophthalmology, Faculty of Health Sciences, Stellenbosch University
Figure 1: Stepwise approach to the management of allergic conjunctivitis
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A stepwise approach to the management of ocular allergies 
is important in preventing unnecessary or inadvertent 
overtreatment of the underlying condition (Figure 1).
Acute allergic conjunctivitis
Acute allergic conjunctivitis describes the immediate 
response seen in sensitised individuals, typically children, 
after exposure to a particular allergen or sensitising agent, 
usually pollen or cat dander.2
Clinical picture and management
Acute allergic conjunctivitis is characterised by episodes 
of intense itching and watering, associated with severe 
conjunctival chemosis and lid swelling (Figure 2).
The condition is self-limiting and settles promptly with 
the removal of the offending allergen. Cool compresses 
and artificial tears can be applied to reduce symptoms 
considerably, but topical and/or oral antihistamines may be 
required in selected cases, i.e. management steps 1-5.
Seasonal and perennial allergic 
conjunctivitis
Seasonal allergic conjunctivitis, also known as hay fever 
conjunctivitis, represents the most common form of allergic 
conjunctivitis.6 The seasonal nature of the condition relates 
to the appearance of specific allergens, most notably tree 
and grass pollens, although the specific allergen may vary 
with geographical location. There is often associated rhinitis 
and/or a history of atopy.
Perennial allergic conjunctivitis represents a more chronic 
form. Generally, signs and symptoms are present throughout 
the year. Notable allergens include house dust mites, animal 
dander and mould.
Clinical picture and management
Patients present with transient attacks of ocular itching, 
tearing and redness. Classic examination findings include 
conjunctival injection (Figure 3), eyelid oedema, as well as 
varying degrees of chemosis (conjunctival oedema).
Management starts with the identification and removal 
of the offending allergen, if possible. Mild cases should 
respond to antigen dilution, cold compresses and short-
term use of topical vasoconstrictors, i.e. management steps 
2-4. Moderate cases may require the addition of topical and 
oral antihistamines, i.e. management step 5, while more 
severe and/or chronic cases often require the use of topical 
mast cell stabilisers, MMAs and topical corticosteroids, i.e. 
management steps 6-9.
Vernal and atopic keratoconjunctivitis 
Vernal keratoconjunctivitis (VKC) is a chronic bilateral corneal 
and conjunctival inflammatory condition that predominantly 
affects young boys who often have a personal or family 
history of atopy. The disease is more common in warm, 
dry climates, where patients may experience symptoms 
throughout the year. In temperate climates, VKC tends to be 
seasonal and often flares up during spring. Fortunately, the 
frequency and severity of attacks subsides in most patients 
as they reach puberty.
Clinical picture and management
VKC characteristically presents with symptoms of intense 
itching, associated with tearing, photophobia, a mucoid 
discharge and a foreign body sensation. The disease usually 
presents in two ways, either as a palpebral or limbal type, 
although both may coexist in a patient.
In the palpebral form, there is diffuse papillary hypertrophy 
under the upper lid that is associated with thick mucoid 
deposition between the papillae (Figure 4). The limbal form 
is characterised by the presence of gelatinous papillae on 
the limbal conjunctiva, which often contain distinct white 
nodules called Horner-Trantas dots (Figure 5). This form 
is frequently seen in more pigmented patients who live 
in hotter climates. The cornea may also be affected with 
erosions and dry white plaques called shield ulcers in 
severe cases (Figure 6).
Similar to VKC, atopic keratoconjunctivitis (AKC) is a 
severe, chronic form of ocular allergy which presents 
Figure 2: Acute	allergic	conjunctivitis: Conjunctival chemosis and lid 
swelling
Figure 3: Seasonal	and	perennial	allergic	conjunctivitis: Acute 
conjunctival injection
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with symptoms of intense itching, mucoid discharge, 
photophobia and blurry vision. It has a strong association 
with atopic dermatitis. Features that distinguish AKC from 
VKC are the location of papillae under both the upper and 
lower eyelids, as opposed to only the upper eyelid in VKC. 
Perennial symptoms and onset, beginning in the second 
or third decade, are other distinguishing features. Eyelid 
changes, such as thickening and keratinisation of eyelid 
margins, are also more prevalent in AKC (Figure 7).
The management of VKC is similar to that of AKC, and 
involves a multipronged approach with environmental, 
systemic and topical measures to control the disease. 
Treatment duration is typically long term and requires 
frequent follow-up. Allergen avoidance is important in the 
treatment process, i.e. management step 1, similar to that 
in other atopic conditions. While antigen dilution, cold 
compresses, topical vasoconstrictors and antihistamines 
provide short-term relief, topical mast cell stabilisers may 
reduce both the frequency of acute exacerbations and 
the need for corticosteroids. Therefore, they form the 
cornerstone of treatment, i.e. management steps 2-6. 
Topical MMAs and NSAIDs are useful treatment options in 
moderate cases, i.e. management steps 7 and 8. Topical 
immunomodulatory drugs, such as corticosteroids and 
cyclosporine, are often required in severe or refractory 
cases, but should preferably be taken under specialist 
supervision, i.e. management steps 9 and 10.
Giant papillary conjunctivitis
Giant papillary conjunctivitis (GPC) is typically seen in 
association with contact lens wear. However, it may also be 
associated with a variety of other foreign objects, such as 
ocular prostheses or exposed sutures.
Clinical picture and management
Symptoms of GPC include a foreign body sensation, 
itching, redness and decreased contact lens tolerance. A 
mucoid discharge is also commonly present. Eversion of 
the upper lid reveals giant papillae, similar to those seen in 
VKC. The papillae are easily visible, but examination with 
a cobalt blue light, after installation of topical fluorescein, 
delineates the papillae more clearly, and in severe cases, 
apical staining of the papillae may be observed.4
Management may require the use of almost all of the steps, 
but begins, as always, with the removal of any offending 
stimuli. In cases that are triggered by contact lens wear, 
reducing the wearing time, increasing the frequency of lens 
replacement, improving lens cleaning to reduce protein 
build-up, as well as changing the lens design or material, 
may prove to be helpful. 
Topical antihistamines, mast cell stabilisers and combination 
agents can all provide relief from the symptoms. Usually, 
Figure 4: Palpebral	vernal	disease: Diffuse subtarsal papillae
Figure 5: Limbal	vernal	disease: Limbal papillae and Horner-Trantas 
dots
Figure 7: Eyelid	thickening	and	keratinisation: Eyelid thickening and 
keratinisation in atopic keratoconjunctivitis
Figure 6: Corneal	involvement	in	vernal	disease:	Shield ulcer and 
plaque
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topical steroids are reserved for use in severe, refractory 
cases of GPC. Ideally, these patients should be managed in 
conjunction with an ophthalmologist.
Toxic conjunctivitis
Toxic conjunctivitis, while not truly allergic in nature, 
is frequently confused with allergic conjunctivitis, and 
may occur following the administration of ophthalmic 
medication.7 Preservatives in ophthalmic medication and 
contact lens solution, most notably benzalkonium chloride 
and thiomersal, are the most common causes.
Clinical picture and management
Unilateral or bilateral conjunctival hyperaemia and a mixed 
follicular or papillary reaction of the palpebral conjunctiva 
are characteristic initial findings. Ideally, this is seen with 
the aid of a slit lamp, but may be observed with a direct 
ophthalmoscope, if large enough. Occasionally, progressive 
conjunctival scarring may ensue and lead to contraction 
of the conjunctival fornices. Corneal punctate epithelial 
erosions, especially of the inferior cornea, may also be 
present.
Treatment involves identifying and removing the offending 
agent. Symptomatic patients may benefit from using 
cold compresses and preservative-free artificial tears, i.e. 
management steps 1-3.
Conclusion
Allergic conjunctivitis represents a diverse group of 
disorders, with many overlapping clinical manifestations. 
Distinguishing between the various subtypes is important 
and can be achieved by taking a thorough history and 
conducting a careful clinical observation. Avoidance of the 
offending allergen is the primary behavioural modification 
for all types of allergic conjunctivitis, and serves as the 
starting point for a common stepwise approach to the 
management of ocular allergy. 
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Sandoz, the generic pharmaceuticals division of Novartis, has 
launched Nexmezol. Nexmezol is the first generic esomeprazole 
in South Africa. 
Nexmezol is indicated for the treatment of gastro-oesophageal 
reflux disease (GORD), a digestive disorder that affects the lower 
oesophageal sphincter, the muscle connecting the oesophagus 
with the stomach. 
In South Africa alone, more than 4,2 million boxes of prescription 
medicine for heartburn are sold annually1.  Poor diet and a stressful 
lifestyle are contributing factors. 
“Lifestyle diseases, coupled with high costs make it increasingly 
difficult for South African patients to gain access to affordable 
treatment for their healthcare problems. Medical aids often do not 
pay for medicines that treat gastro-oesophageal reflux disease, 
therefore it is mostly funded out of the acute/savings portion of 
medical aids ” says Carnie van der Linde Country Head for South 
East Africa.
Research shows that patients with GORD are bothered and even 
incapacitated by their symptoms, and that their health-related 
quality of life is impaired as a result. 2   Patients with heartburn 
experience worse pain, social functioning and emotional wellbeing 
than those with diabetes, hypertension and acute coronary events.3
The proton pump inhibitor (PPI) in Nexmezol is often a solution for 
sufferers who have tried other alternatives. Nexmezol is effective in 
acid suppression.4
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